News | November 16, 2023
Sanofi completes closing for potential first-in-class vaccine against ExPEC
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
The collaboration brings a seamless digital experience to more formulators worldwide
The newly developed adhesive is available in two different grades. Loctite WT 3001 and Loctite WT 3003 h
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
The companies plan to start a pivotal Phase 3 trial in the coming months
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Additional premium services in RegXcellence will include access to BASF’s Product Carbon Footprint data and direct downloads of audit reports
Subscribe To Our Newsletter & Stay Updated
